Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Stanford Univ. Licenses IVF Technology

Pregnancy health (CDC)

(U.S. Centers for Disease Control)

Auxogyn Inc., a medical technology company in Menlo Park, California  says it acquired an exclusive license from Stanford University to develop products that can help improve the effectiveness of in vitro fertilization (IVF) procedures. Auxogyn specializes in technologies for women’s reproductive health.

A new paper describing the technology licensed from Stanford demonstrates that a human embryo’s fate is already determined at the four-cell stage of development. The paper appears in the current online edition of Nature Biotechnology (paid subscription required). The article indicates that measuring a unique set of non-invasive imaging parameters by day 2 may allow an embryologist to predict the embryos that will reach the blastocyst (day 5) stage of development with a very high degree of accuracy.

Lissa Goldenstein, president of the company, says in a press release that Auxogyn is “developing a product that assesses early embryo viability at the 4-cell stage,” adding “clinical data assessments may enable embryologists to improve the effectiveness of in vitro fertilization.”

2 comments to Stanford Univ. Licenses IVF Technology